BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 30226599)

  • 1. 18F‑alfatide positron emission tomography may predict anti‑angiogenic responses.
    Liu J; Wang D; Meng X; Sun X; Yuan S; Yu J
    Oncol Rep; 2018 Nov; 40(5):2896-2905. PubMed ID: 30226599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
    Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
    Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
    Yang G; Nie P; Kong Y; Sun H; Hou G; Han J
    Tumour Biol; 2015 May; 36(5):3285-91. PubMed ID: 25501513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
    Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
    Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quantitatively evaluating the evolution of the tumor perfusion in A549 lung adenocarcinoma transplantation model induced by antiangiogenic treatment].
    Xiong Z; Deng P; Hu C; Liu J; Yang H; Zhou J; Wang Y; Zhou H; Zhu Z
    Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):306-10. PubMed ID: 26879795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of Integrin α
    Song YS; Park HS; Lee BC; Jung JH; Lee HY; Kim SE
    Cancer Biother Radiopharm; 2017 Oct; 32(8):288-296. PubMed ID: 29053416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric monitoring of early response to antiangiogenic therapy: a sequential perfusion CT and PET/CT study in a rabbit VX2 tumor model.
    Kim JI; Lee HJ; Kim YJ; Kim KG; Lee KW; Lee JH; Lee HJ; Lee WW
    ScientificWorldJournal; 2014; 2014():701954. PubMed ID: 25383376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
    Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
    J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
    Chen FH; Chiang CS; Wang CC; Fu SY; Tsai CS; Jung SM; Wen CJ; Lee CC; Hong JH
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1512-21. PubMed ID: 21621344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma.
    Simard B; Bouamrani A; Jourdes P; Pernod G; Dimitriadou V; Berger F
    Microvasc Res; 2011 Jul; 82(1):6-17. PubMed ID: 21406197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
    Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
    J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy.
    Shi J; Jin Z; Liu X; Fan D; Sun Y; Zhao H; Zhu Z; Liu Z; Jia B; Wang F
    Mol Pharm; 2014 Nov; 11(11):3915-22. PubMed ID: 25158145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.
    Benayoun L; Gingis-Velitski S; Voloshin T; Segal E; Segev R; Munster M; Bril R; Satchi-Fainaro R; Scherer SJ; Shaked Y
    Stem Cells; 2012 Sep; 30(9):1831-41. PubMed ID: 22782858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.